Price1.46%   +0.1300
(After Hours: 9.19 +0.1400 +1.55%)
Apr-21-21 04:45AM KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point CapitalGlobeNewswire
Apr-09-21 08:08AM KemPharm Amends AZSTARYS Licensing Agreement With Gurnet Point Capital AffiliateSmarterAnalyst
07:00AM KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590MBenzinga
Mar-17-21 08:30AM Are Options Traders Betting on a Big Move in KemPharm (KMPH) Stock?Zacks
Mar-11-21 04:25AM KemPharm Reports Fourth Quarter and Full-Year 2020 Financial ResultsGlobeNewswire
02:30AM KemPharm, Inc. to Host Earnings CallACCESSWIRE
Mar-09-21 07:30AM KemPharm to Report Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewswire
Mar-05-21 08:15AM KemPharm Won FDA Approval, But This Analyst Isn’t HappyTipRanks
Mar-04-21 04:41AM KemPharm to Present at the 33rd Annual Roth ConferenceGlobeNewswire
02:47AM Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & MoreZacks
Mar-04-21 02:58AM KemPharma (KMPH) Moves 42.8% Higher: Will This Strength Last?Zacks
Mar-03-21 01:00AM KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, AzstarysZacks
07:56AM KemPharm Pops 93% Pre-Market On FDA Approval Of ADHD TherapySmarterAnalyst
Mar-03-21 07:46AM The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine StudyBenzinga
Mar-02-21 11:31AM KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHDGlobeNewswire
08:01AM The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug DataBenzinga
Feb-28-21 10:54AM Attention Biotech Investors: Mark Your Calendar For March PDUFA DatesBenzinga
Feb-27-21 11:58AM The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More EarningsBenzinga
Feb-05-21 08:30AM Do Options Traders Know Something About KemPharm (KMPH) Stock We Don't?Zacks
Jan-27-21 08:30AM KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use DisorderGlobeNewswire
Jan-14-21 07:30AM KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual ConferenceGlobeNewswire
Jan-13-21 07:30AM KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”GlobeNewswire
Jan-08-21 08:30AM KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital MarketGlobeNewswire
Dec-23-20 06:11AM KemPharm Announces 1-for-16 Reverse Stock SplitGlobeNewswire
Dec-22-20 07:30AM KemPharm Files IND for KP879 for the Treatment of Stimulant Use DisorderGlobeNewswire
Dec-02-20 07:30AM KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDAGlobeNewswire
Nov-30-20 07:30AM REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor EventGlobeNewswire
Nov-23-20 04:30AM KemPharm Provides Update on Development PipelineGlobeNewswire
Nov-18-20 08:30AM KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor EventGlobeNewswire
Oct-29-20 04:05AM KemPharm Reports Third Quarter 2020 Financial ResultsGlobeNewswire
02:45AM KemPharm, Inc.to Host Earnings CallACCESSWIRE
Oct-26-20 08:30AM KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results CallGlobeNewswire
Oct-22-20 07:30AM KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual MeetingGlobeNewswire
Oct-05-20 08:46AM KemPharm and Corium Expand Relationship with New Consultation Services AgreementGlobeNewswire
Sep-30-20 07:55AM 4 Small Drug Stocks to Look Out For Amid Coronavirus UncertaintyZacks
Sep-25-20 05:00AM KemPharm Files Preliminary Proxy for Special Meeting of StockholdersGlobeNewswire
Sep-21-20 08:35AM Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingGlobeNewswire
Sep-14-20 08:35AM Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020GlobeNewswire
Sep-10-20 07:30AM KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain TherapiesGlobeNewswire
Sep-02-20 04:05AM KemPharm to Present at Upcoming September Investor ConferencesGlobeNewswire
Aug-14-20 07:30AM KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDAGlobeNewswire
Aug-12-20 04:05AM KemPharm Reports Second Quarter 2020 Financial ResultsGlobeNewswire
Aug-04-20 07:30AM KemPharm to Report Second Quarter 2020 Financial ResultsGlobeNewswire
Jul-28-20 07:30AM KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484GlobeNewswire
Jun-21-20 10:06AM Edited Transcript of KMPH earnings conference call or presentation 12-May-20 9:00pm GMTThomson Reuters StreetEvents
Jun-18-20 08:30AM KemPharm Issues Letter to ShareholdersGlobeNewswire
May-19-20 07:30AM KemPharm Receives Day-74 Letter for KP415 NDAGlobeNewswire
May-12-20 04:05AM KemPharm Reports First Quarter 2020 Financial ResultsGlobeNewswire
May-06-20 04:15AM KemPharm to Report First Quarter 2020 Financial ResultsGlobeNewswire
May-04-20 08:00AM NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point CapitalGlobeNewswire
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.
Cap:    |  Volume (24h):